Pharma sector boom puts pressure on compliance to counter financial crime
By 
Ruth Prickett2025-12-04T22:15:00
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Globally, the sector is booming. According to Robinson Brothers website, the global pharmaceutical industry is forecast to be worth $1.6 trillion this year. Costs are also high. It typically costs up to £1.15bn to develop and market a new treatment – which can take more than 12 years – and 95 percent of all experimental medicines studied for human treatment fail to achieve approval.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleU.K. asset managers to focus on investor engagement outcomes under new reporting guidance
Asset managers reporting under the U.K.’s updated Stewardship Code starting Jan 1 should focus on engagement outcomes and evidence of impact. New guidance from the U.K. financial regulator offers case studies and checklists to support compliance.
-
ArticleNew regulatory regimes for U.K. and EU ESG ratings firms could increase compliance costs
Environmental ratings are becoming big business as companies seek proof of sustainable and socially beneficial conduct. Firms that issue ratings on environmental, social and governance (ESG) performance are set to be regulated in the EU and U.K.
-
ArticleU.K. Cyber Security and Resilience bill set to regulate critical infrastructure suppliers
Suppliers to the U.K. critical infrastructure will face new regulations to ensure they are protected from cyberattacks. The Cyber Security and Resilience Bill, introduced on November 12, also raises penalties for breaches and expands regulator powers to label certain suppliers as critical.
More from Regulatory Policy
-
ArticleSEC closes FCPA probe into Calavo Growers
The Securities and Exchange Commission has closed its Foreign Corrupt Practices Act investigation into Calavo Growers, three months after the Department of Justice closed its FCPA investigation into the produce and agriculture company.
-
ArticleU.K. Employment Rights Act will lead to rise in tribunal claims
The number of U.K. employment tribunal cases could rise following reforms in the Employment Rights Act 2025. Several changes take effect this year, including shorter unfair dismissal qualifying periods, day-one worker rights, stronger protections for pregnant women, and an end to exploitative contracts.
-
ArticleU.K. government scraps long-awaited audit reforms to prioritize growth
Long-awaited reforms to the U.K. audit regime have been “scrapped” from the government’s legislative plans. The decision has led to an outburst of disappointment and frustration from audit bodies and pension funds that argued the reforms would increase trust in companies and support growth.